| Name | Title | Contact Details |
|---|
Synapse Medical Communications is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Synapse Medical Communications, please visit www.synapseny.com
Gateway Community Health Center, Inc. is a community health center funded by the U.S. Department of Health and Human Services. The Center is a 501 (c) (3) private, non-profit corporation with a governing board of 15 directors whose responsibility is t...
Founded in 1955 and located on a 30-acre campus in Sellersville, Pennsylvania, Penn Foundation is a not-for-profit organization providing innovative services that address the mental health, substance use, and intellectual disability needs of our community. Through a broad range of diverse programs that can be tailored to meet individual needs, Penn Foundation provides compassionate, responsive care to more than 10,000 children, adolescents, and adults each year. Our tradition of compassionate care combined with a strong belief in the healing power of hope and the possibility of recovery enables us to help individuals and families grow, develop, and recover to their fullest mental, emotional, and spiritual health.
Westside Health Inc is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.